本文已被：浏览 1800次 下载 16次
中文摘要: 目的 对慢性阻塞性肺病患者给予支气管扩张剂联合吸入性糖皮质激素治疗，并对临床疗效和患者生活质量的影响情况进行观察。方法 选取2016年3月—2017年3月医院收治的慢性阻塞性肺病(COPD)患者80例，根据随机数字表法将其分为研究组和对照组。给予对照组支气管扩张剂进行治疗，给予研究组支气管扩张剂联合吸入性糖皮质激素进行治疗。对两组治疗前后肺通气功能、血气分析情况、生活质量评分、临床疗效和不良反应等进行比较分析。结果 在各项肺通气功能指标(FEV1、FVC、FEV1/FVC)方面，两组治疗后均较治疗前明显提高，且研究组提高程度显著优于对照组(P＜0.05)；在血气分析方面，两组治疗后血氧分压(PaO2)明显提高，动脉二氧化碳分压(PaCO2)明显降低，且研究组各指标改善程度均显著优于对照组(P＜0.05)；在生活质量(SF-36)评分方面，研究组得分均较对照组明显提高，差异具有统计学意义(P＜0.05)；治疗后，研究组治疗总有效率95.0%较对照组75.0%明显提高，差异具有统计学意义(P＜0.05)；在不良反应方面，两组发生率间比较差异无统计学意义(P＞0.05)。结论 对慢性阻塞性肺病患者给予支气管扩张剂联合吸入性糖皮质激素治疗能够取得显著的临床疗效，可使患者肺通气功能、血气状况和生活质量明显改善，且疗效安全可靠，对稳定患者病情具有非常重要的价值，值得临床进一步推广应用。
Abstract:OBJECTIVE To observe the effect of bronchodilator combined with inhaled glucocorticoid therapy on the clinical efficacy and quality of life of patients with chronic obstructive pulmonary disease (COPD).METHODS From March 2016 to March 2017 Eighty patients with chronic obstructive pulmonary disease (COPD) were randomly divided into study group and control group according to the random number table method. The The control group was treated with bronchodilator, and the study group was treated with bronchodilator combined with inhaled glucocorticoid. The pulmonary ventilation function, blood gas analysis, quality of life score, clinical efficacy and adverse reactions were analyzed before and after treatment.RESULTS In the aspects of FEV1, FVC, FEV1 / FVC, the two groups were significantly improved compared with those before treatment, and the improvement of the study group was significantly better than that of the control group(P＜0.05).In the quality of life (SF-36) score, the scores of the study group were significantly higher than those of the control group (P <0.05). The scores of PaCO2 were significantly lower than those of the control group (P <0.05). After treatment, the total effective rate of the treatment group was significantly higher than that of the control group(P＜0.05).In the adverse reaction, There was no significant difference between the two groups(P＞0.05).CONCLUSION Bronchodilator combined with inhaled glucocorticoid therapy in patients with chronic obstructive pulmonary disease can achieve significant clinical curative effect, which can improve the pulmonary ventilation function, blood gas condition and quality of life in patients with chronic obstructive pulmonary disease, and the effect is safe and reliable. Has a very important value, it is worth further clinical application.
keywords: bronchodilator inhaled glucocorticoid chronic obstructive pulmonary disease eefficacy quality of life
文章编号：3201801026 中图分类号：R977.1 文献标志码：
基金项目:
引用文本：